July 1 2020

Breakthrough data for systemic therapies in the treatment of various hematologic malignancies impressed attendees at the American Society of Clinical Oncology 2020 Virtual Scientific Program.

Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.